Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
1 finding from 1 review
Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes improvement in disability grade Defined as achievement of a… compared with placebo (very low certainty).
1 finding from 1 review
Change in disability after 4 weeks disability grade change. Scale from: 0 to 10. · patients with Guillain‐Barré syndrome
1 finding from 1 review
Number improved by 1 or more disability grades after 4 weeks · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in number improved by 1 or more disability grades after 4 weeks compared with PE (moderate certainty).
1 finding from 1 review
Dead or disabled after 12 months (48 weeks) · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in dead or disabled after 12 months (48 weeks) compared with PE (low certainty).
1 finding from 1 review
Relapse or treatment‐related fluctuation · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in relapse or treatment‐related fluctuation compared with PE (low certainty).
1 finding from 1 review
Patients in whom treatment was discontinued · patients with Guillain‐Barré syndrome
IVIg leads to lower participants in whom treatment was discontinued compared with PE (high certainty).
1 finding from 1 review
Number of patients with adverse events attributed to treatment · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in number of participants with adverse events attributed to treatment compared with PE (moderate certainty).
1 finding from 1 review